Rhumbline Advisers Bio N Tech Se Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Bio N Tech Se stock. As of the latest transaction made, Rhumbline Advisers holds 148 shares of BNTX stock, worth $15,729. This represents 0.0% of its overall portfolio holdings.
Number of Shares
148
Previous 149
0.67%
Holding current value
$15,729
Previous $13,000
15.38%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BNTX
# of Institutions
321Shares Held
40.9MCall Options Held
1.38MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$854 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$450 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$425 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$382 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$201 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.8B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...